Clinical trial · Interventional
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
NCT02529579CI-TRIAL-00018905unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Pancreatic Ductal | Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| iAPA-DC/CTL adoptive cellular immunotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Gemcitabine
- description
- Standard Gemcitabine Therapy
- interventionNames
- Drug: Gemcitabine
- type
- EXPERIMENTAL
- label
- cellular immunotherapy & Gemcitabine
- description
- iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
- interventionNames
- Other: iAPA-DC/CTL adoptive cellular immunotherapy
- Drug: Gemcitabine
Primary outcomes (1)
- measure
- 6-month SR
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Advanced Pancreatic cancer patients with histological pathology confirmation 2. Both gender, aged 18-70 year-old 3. Bone marrow functioned well 4. Renal function normal 5. Liver function normal 6. patients are voluntary, and willing to sign informed consent 7. expected lifetime was at least 3 months Exclusion Criteria: 1. With acute inflammation 2. Accompanied with primary malignant tumor other than pancreas 3. with autoimmune disease 4. using corticosteroid or other suppress immune hormone treatment 5. had transplant operation of vital organs 6. active hepatitis 7. HIV positive 8. dysfunction in blood coagulation 9. serious diseases in circulatory and respiratory systems 10. pregnancy or breast-feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.